Table 1.

Overview of demographic data and clinical features of 71 MPN patients with 71 arterial and venous thromboembolic events (ATE/VTE) treated with either VKA or DOAC

Male/female; n (%)	22/49 (31.0/69.0)
Median age at first ATE/VTE; years (range)	54.0 (22.0–82.0)
Median follow-up time from first ATE/VTE; years (range)	3.2 (0.1–20.4)
MPN diagnosis
Polycythemia vera (PV); n (%)	30 (42.3)
Myelofibrosis (MF); n (%)	20 (28.2)
Essential thrombocythemia (ET); n (%)	19 (26.8)
MPN unclassifiable; n (%)	2 (2.8)
Driver mutations
JAK2; n (%)	63 (88.7)
CALR; n (%)	3 (4.2)
MPL; n (%)	1 (1.4)
Triple negative; n (%)	2 (2.8)
Unknown; n (%)	2 (2.8)
ATE/VTE
VTE; n (%)	62 (87.3)
ATE; n (%)	9 (12.7)